Results 31 to 40 of about 112,380 (305)
Journal for ImmunoTherapy of Cancer, 2021 Background Poly(ADP-ribose) polymerase (PARP) inhibitors (eg, olaparib) are effective against BRCA-mutated cancers at/near maximum tolerated doses by trapping PARP-1 on damaged chromatin, benefitting only small patient proportions.
Dorota Wyczechowska +12 more
doaj +1 more source
PARP inhibition: a promising therapeutic target in ovarian cancer [PDF]
, 2015 Ovarian cancer is burdened by the highest mortality rate among gynecological cancers. Gold standard is represented by the association of platinum-taxane -based chemotherapy and radical surgery.
Abdul Halim, T +14 more
core +1 more source
Inhibition of Poly(ADP-Ribose) polymerase enhances the toxicity of 131I-Metaiodobenzylguanidine/Topotecan combination therapy to cells and xenografts that express the noradrenaline transporter [PDF]
, 2012 Targeted radiotherapy using [131I]meta-iodobenzylguanidine ([131I]MIBG) has produced remissions in some neuroblastoma patients. We previously reported that combining [131I]MIBG with the topoisomerase I (Topo-I) inhibitor topotecan induced long-term DNA ...
Babich, John W +7 more
core +1 more source
Journal of the Turkish German Gynecological Association, 2015 Polyadenosine diphosphate (ADP) ribose polymerase (PARP) lends a panoramic view to the inner mystery of protection of integrity of deoxyribonucleic acid (DNA) in a cell genome. They are a balancing part of an even more dynamic equilibrium of normalcy against daily assaults.
Chinmoy K, Bose, Nirban, Basu
openaire +2 more sources
Journal of Experimental & Clinical Cancer Research, 2018 Background Targeting poly ADP-ribose polymerase (PARP) has been recently identified as a promising option against gastric cancer (GC). However, PARP inhibitors alone achieve limited efficacy.
Xiaoting Lin +7 more
doaj +1 more source
Structure, function and inhibition of poly(ADP-ribose)polymerase, member 14 (PARP14) [PDF]
, 2018 Poly(ADP-ribose)polymerase, member 14 (PARP14, alternatively named ARTD8, BAL2, and COAST6) is an intracellular mono(ADP-ribosyl) transferase. PARP14 transfers a negatively charged ADP-ribose unit from a donor NAD+ molecule onto a target protein, post ...
Levonis, Stephan M +3 more
core +1 more source
Haematologica, 2009 Background Aberrant or impaired repair of double-strand DNA breaks is a common feature of de novo acute myeloid leukemia and myelodysplastic syndromes.
Terry J. Gaymes +6 more
doaj +1 more source
WEE1 and PARP-1 play critical roles in myelodysplastic syndrome and acute myeloid leukemia treatment
Cancer Cell International, 2023 Background Myelodysplastic syndrome (MDS) is a clonal bone marrow disorder defined by cytopenia and is associated with an increased risk of transformation to acute myeloid leukemia (AML).
Seiichi Okabe +3 more
doaj +1 more source
The novel mTOR inhibitor RAD001 (Everolimus) induces antiproliferative effects in human pancreatic neuroendocrine tumor cells [PDF]
, 2007 Background/Aim: Tumors exhibiting constitutively activated PI(3) K/Akt/mTOR signaling are hypersensitive to mTOR inhibitors such as RAD001 (everolimus) which is presently being investigated in clinical phase II trials in various tumor entities, including
Albert JM +35 more
core +1 more source
Synthetic lethality of PARP and NAMPT inhibition in triple‐negative breast cancer cells
EMBO Molecular Medicine, 2012 PARP inhibitors have been proposed as a potential targeted therapy for patients with triple‐negative (ER‐, PR‐, HER2‐negative) breast cancers. However, it is as yet unclear as to whether single agent or combination therapy using PARP inhibitors would be ...
Ilirjana Bajrami +6 more
doaj +1 more source